Trump announces phased tariff plan for imported generic medicines

US President Donald Trump has announced a phased tariff plan for imported generic medicines, saying the policy is intended to push pharmaceutical manufacturing back to the United States. The announcement was made in a post on Truth Social and sets out a schedule that would begin on 1 August. It immediately drew attention in markets because of the scale of India's role in supplying generic drugs to the US.

Sponsored

Under the plan, generic medicines entering the US would face a zero tariff for two years, before rising to 100% for one year and then to 200% from the third year onward. Trump said the measure would create a penalty for companies that choose not to build plants and equipment within the time allowed. He also said the existing approach to patented, branded and innovative drugs would remain unchanged.

The announcement prompted a quick reaction in Indian equities, with the Nifty Pharma index falling nearly 2% in early trade. Shares of major exporters including Sun Pharmaceutical Industries, Cipla, Dr Reddy's Laboratories, Lupin and Aurobindo Pharma also fell by up to around 2.5%. The broader Indian market weakened as well, with the Nifty 50 and the BSE Sensex both lower, while traders also tracked higher crude oil prices linked to the widening Middle East conflict.

The policy matters because India is widely described as the largest exporter of generic drugs to the US and is often referred to as the pharmacy of the world. According to the figures cited in the report, India exported pharmaceuticals worth $9.7bn to the US in 2025, equal to 38% of its total global pharma exports of $25.8bn. That makes the US market central to the earnings outlook for Indian drugmakers, especially those with large generic portfolios.

Sponsored

Generic medicines from India are used in treatments ranging from high blood pressure and diabetes to cancer, infectious diseases and mental health conditions. The tariff plan therefore has implications not only for manufacturers and investors, but also for supply chains that support lower-cost medicines in the US. It also fits a broader protectionist manufacturing message from Trump, who framed the move as a way to encourage domestic production.

What remains unclear is how the tariff schedule would be implemented in practice and how companies with US-based subsidiaries would be treated. A brokerage cited in the report said the plan may not seriously hurt Indian drugmakers, but that view will depend on the final rules and any exemptions. Investors will now be watching for further clarification from the US administration, as well as any response from Indian pharmaceutical companies and trade officials.

#Trump #genericmedicines #tariffs #Indiapharma #UStradepolicy